Biomiga Diagnostics will be presenting at PCRS 2012, Rancho Las Palmas, California, on April 20th.
Biomiga Diagnostics will be presenting data on its population pharmacokinetic/Therapeutic Monitoring Device for Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), and Human chorionic gonadotropin (hCG) in personalized IVF treatment.
April 9, 2012 - PRLog -- Biomiga Diagnostics, Fountain Valley, a molecular diagnostics company, announced today that it will be presenting a poster―Therapeutic Drug Monitoring (TDM) point-of-care assays for LH, FSH, and hCG―at PCRS 2012. IVF has a delivery rate per started cycle of around 22% and close to 250,000 children where 26% of pregnancies were twins and 2.5% triplets. IVF Protocols —with a target of generating between 8 and 15 oocytes—are complex, time consuming, expensive and may give rise to considerable patient discomfort and increased chance of complications, especially the ovarian hyperstimulation syndrome (OHSS). The drug regimen used most often for ovarian hyperstimulation consists of a steroid contraceptive pretreatment to regulate the menstrual cycle, GnRH agonist analogues to suppress LH release in the pre-stimulation cycle, daily gonadotropin injections for almost 2 weeks to promote the development of multiple egg follicles, as well as a bolus dose of hCG to induce ovulation of the mature oocytes. In many countries, medication and monitoring expenses outweigh the cost of the IVF procedure itself. A shift in emphasis from mild stimulation towards mild ovarian response is ongoingto reduce both cancellation and over-response rates by developing more individualized treatment regimens based on initial patient characteristics, such as age, body weight and ovarian reserve characteristics. To facilitate individualized treatment regimens that would reduce the cost of medication and OHSS risk due to overmedication, we have developed point-of-care therapeutic drug monitoring of the gonadotropins widely used in IVF―FSH, LH, and hCG. Here, Dr. Larn Hwang and colleagues describe the development of rapid point-of-care tests for detection of these hormones that are quantitative and applicable to plasma, serum, as well as urine. As TDM, these tests allow for more effective dosing of the patients that should result in reduced cost and incidences of OHSS from overmedication. These findings will be presented at the 60th Annual Meeting of The Pacific Coast Reproductive Society, April 18-22, 2012, Rancho Las Palmas, California.
Abstract S10: Therapeutic Drug Monitoring (TDM) Point-of-Care Assays for LH, FSH, and hCG. Larn Hwang, Chao Hsiao, Vuong Trieu. This poster has been scheduled for presentation on Friday, April 20 from 5:30 to 7 PM in the Exhibit Hall at the Rancho Las Palmas Resort.
PCRS is a global, interactive organization that champions the field of reproductive medicine. The Core Values we believe in are supportiveness, innovation, inclusiveness, collegiality, professional and personal development, and intimacy. PCRS is a multidisciplinary medical specialty society providing Continuing Medical Education (CME) to physicians and allied healthcare professionals. PCRS offers the highest quality, innovative CME, designed and presented by thought leaders in reproductive medicine. PCRS provides an outstanding forum for the exchange of information, and the advancement of the ideologies of reproductive medicine in a relaxed and collegial setting building relationships that foster the integration of current knowledge to ensure quality medical care for patients.
About Biomiga Diagnostics
The executives of Biomiga Diagnostics are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing. With more than a decade of drug development experience, the leadership team has expertise ranging from basic/applied research, preclinical/
Larn Hwang PhD
Chief Operating Officer
Kouros Motamed PhD
Chief Technology Officer
# # #
Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine,